Global pharma companies that have publicly announced Trump drug pricing agreements

President Trump secured agreements with 16 of 17 major pharma firms to align U.S. prescription drug prices with those in other developed nations in exchange for three-year tariff exemptions. Several companies committed deep discounts (up to 85% for Pfizer; AstraZeneca up to 80%); Novo Nordisk cut Wegovy/Ozempic from ~$1,000/$1,350 to $350 via TrumpRx and will offer insulins at $35/month; Lilly capped certain obesity drugs at $50/month for Medicare. The deals are sector-moving and imply meaningful revenue/price pressure on drugmakers while expanding direct-to-consumer distribution via TrumpRx.gov; Regeneron remains unsigned.

Analysis

The headline-driven repricing of US pharma economics shifts profits from entrenched list-price pockets into volume, direct-to-patient margins, and government‑negotiated channels. For firms with concentrated US revenue (roughly ~30–50% of sales) and a small number of high-margin blockbusters, expect a 5–12% hit to EBITDA over 12–24 months unless offset by cost cuts, higher volumes or faster biosimilar/generic rollouts; these moves compress launch economics and lower IRRs on new molecular assets by several hundred basis points.

Second-order winners are payers and distribution channels that capture lower acquisition costs and can reprice formularies; losers include companies with concentrated exposure to a handful of branded franchises or with heavy gross-to-net variability. Near-term capex and operational effects are non-trivial — expect incremental manufacturing and compliance capex for onshoring to rise by $0.5–1.5bn for a large-cap over 1–3 years, tightening free cash flow profiles even if headline revenue holds.

Key catalysts and risks: election and regulatory reversals are binary within 6–18 months and could unwind prices quickly; litigation and contract renegotiations can delay impact into multiple reporting periods. Clinical readouts, patent cliffs, and international reference price movements remain dominant idiosyncratic drivers and can swamp policy effects in any 3–12 month window.

Consensus is focused on headline downside for growth-at-risk names; less appreciated is that commitments are time‑limited and operationally costly to sustain, creating event windows (earnings, midterm political calendar) where relative re‑ratings can be rapid. That generates attractive asymmetric, event-driven trades: short concentrated-exposure equities into 6–12 month catalysts while buying defensive/scale names that can fund capex without diluting R&D cadence.

Key Decisions for Investors

• Pair trade (relative value): Short NVO via a 6–12 month put‑spread (buy 12m 15% OTM put / sell 12m 10% OTM put) sized ~1% NAV and go long JNJ stock or 12m 5% ITM calls with equal dollar risk. R/R: target 25–35% relative outperformance for the pair over 6–12 months; stop/flip if spread moves against you by 10% absolute.
• Event‑driven hedge: Buy GILD 6–9 month 20/12.5% put spread (defined risk) sized 0.5–1% NAV to protect vs further pricing squeezes ahead of its next major earnings/guide; payoff targets ~30% downside in equity but limited premium loss if policy momentum rolls back.
• Convex long (defensive optionality): Buy NVS 9–12 month call spreads (buy 12m 15% OTM call / sell 12m 40% OTM call) to capture a re‑rating if market rotates into scale/launch resilience. Expect 20–40% upside with limited premium; allocate 0.75–1% NAV.
• Tactical reallocation: Trim high-exposure growth names (AMGN, SNY, ABBV) by 10–20% and redeploy into JNJ/PFE for 3–12 month defensive carry. Risk/reward: lowers portfolio volatility and funds optionality into event windows (earnings, political inflection) — set trailing stops at 12–15% per position.